Sanofi's Adlyxin slightly safer than Novo Nordisk blockbuster but effectiveness questions remain, report says
A new comparison claims that Adlyxin (lixisenatide), a drug from French pharma major Sanofi (Euronext: SAN) which gained US Food and Drug Administration (FDA) approval last month for type 2 diabetes, is safer than a top-selling treatment marketed by Novo Nordisk (NOV: N).
Advera Health Analytics has compared Adlyxin, a once-daily mealtime glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection indicated as an adjunct to diet and exercise, with thje Danish company’s Victoza (liraglutide) and Byetta (exenatide), sold by Anglo-Swedish pharma major AstraZeneca (LSE: AZN).
The report states: “Adlyxin showed a slightly safer profile compared to Victoza based on a lower serious adverse events rate in head-to-head trials, and no associated thyroid cancer risk which has been tied to Victoza in rare cases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze